Thomas Pabst

High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

Bob Löwenberg, Gert J. Ossenkoppele, Wim van Putten et al. · New England Journal of Medicine · 2009 · 822 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Molecular Minimal Residual Disease in Acute Myeloid Leukemia

Mojca Jongen‐Lavrencic, Tim Grob, Diana Hanekamp et al. · New England Journal of Medicine · 2018 · 781 citations · Full text

Medicine, Hematology, Molecular Biology +17

High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study

Monique Terwijn, Wim L.J. van Putten, Angèle Kelder et al. · Journal of Clinical Oncology · 2013 · 449 citations · Full text

Medicine, Hematology, Oncology +16

Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial

Hans Theodor Eich, Volker Diehl, Helen Görgen et al. · Journal of Clinical Oncology · 2010 · 436 citations · Full text

Medicine, Oncology, Radiation Oncology +16

Cytarabine Dose for Acute Myeloid Leukemia

Bob Löwenberg, Thomas Pabst, Edo Vellenga et al. · New England Journal of Medicine · 2011 · 407 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17